Monday, December 23, 2024
HomeTagsTolerability

tolerability

First Subject Enrolled in Phase II/III Study of Eisai’s Alzheimer Antibody

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced that the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), led by Washington University School...
0FansLike
3,912FollowersFollow
0SubscribersSubscribe
spot_img

Hot Topics